Stocks › MRNA
Moderna, Inc.
MRNA·Nasdaq·
United States·USD
$195.00
-4.33 (-2.17%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
MRNA
Moderna, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
MRNAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of MRNA by members of U.S. Congress · 77 on record · 15 in the last 12 months
Whale Activity
Position changes in MRNA reported for 2026-09-30 by 1121 institutional filers
- Increased298
- New329
- Held114
- Decreased259
- Closed68
- No prior filing53
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 59.0M | $11.35B | increased |
| BlackRock, Inc. | 27.8M | $5.35B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 23.9M | $4.61B | increased |
| Capital World Investors | 22.6M | $4.36B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 15.8M | $3.04B | increased |
| STATE STREET CORP | 15.5M | $2.98B | decreased |
| BAILLIE GIFFORD & CO | 11.4M | $2.20B | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 10.2M | $1.97B | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.6M | $1.47B | increased |
| Theleme Partners LLP | 6.7M | $1.28B | decreased |
| MORGAN STANLEY | 6.0M | $1.16B | decreased |
| GOLDMAN SACHS GROUP INC | 5.9M | $1.14B | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by MRNA insiders, by quarter · Form 4
Recent Insider Transactions
4,031 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Hoge StephenPresident | Sale | −5,082 | $212.57 | $1.1M | Nov 17, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −34.0K | $211.45 | $7.2M | Nov 17, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −157 | $214.19 | $34K | Nov 17, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −39.2K | $219.66 | $8.6M | Nov 16, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −39.1K | $220.72 | $8.6M | Oct 15, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −450 | $214.15 | $96K | Oct 14, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −38.8K | $213.47 | $8.3M | Oct 14, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −40.3K | $146.07 | $5.9M | Sep 15, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Option exercise | +76.5K | $12.21 | $933K | Sep 15, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −40.3K | $144.13 | $5.8M | Sep 14, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Option exercise | +76.5K | $12.21 | $933K | Sep 14, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Sale | −15.0K | $134.49 | $2.0M | Sep 10, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Sale | −19.8K | $134.49 | $2.7M | Sep 10, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Option exercise | +19.8K | $30.96 | $614K | Sep 10, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Tax withholding | −5,704 | $148.87 | $849K | Sep 4, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Option exercise | +11.8K | — | — | Sep 4, 2026 | Form 4 ↗ |
| Klinger Shannon ThymeChief Legal Officer | Tax withholding | −5,704 | $148.87 | $849K | Sep 4, 2026 | Form 4 ↗ |
| Klinger Shannon ThymeChief Legal Officer | Option exercise | +11.8K | — | — | Sep 4, 2026 | Form 4 ↗ |
| Klinger Shannon ThymeChief Legal Officer | Tax withholding | −1,048 | $140.34 | $147K | Sep 1, 2026 | Form 4 ↗ |
| Klinger Shannon ThymeChief Legal Officer | Option exercise | +2,166 | — | — | Sep 1, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding MRNA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Growth Fund of America | 15.0M | $2.10B | 0.60% | Aug 31, 2026 |
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 8.2M | $1.16B | 1.18% | Aug 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 11.3M | $793.6M | 0.03% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 4.6M | $643.3M | 0.07% | Aug 31, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 9.2M | $641.1M | 0.04% | Jun 30, 2026 |
| VANGUARD INTERNATIONAL GROWTH FUND VANGUARD WORLD FUND | 4.3M | $603.1M | 1.35% | Aug 31, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 8.2M | $573.6M | 0.30% | Jun 30, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 5.2M | $363.3M | 0.54% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 4.9M | $340.1M | 0.04% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund Fidelity Mt. Vernon Street Trust | 2.4M | $332.6M | 1.18% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list MRNA's shares (CUSIP 60770K107), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 58.9M shares14.8%
Nov 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 58.9M shares14.8%
Nov 5, 2026 · ↗ - Capital World InvestorsSCHEDULE 13G · passive (13G) · 22.3M shares5.6%
Aug 12, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 51.8M shares13.1%
Aug 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 51.8M shares13.1%
Aug 6, 2026 · ↗ - BAILLIE GIFFORD & COSCHEDULE 13G/A · passive (13G) · 18.2M shares4.6%
Jul 24, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 25.9M shares6.5%
Apr 30, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming moderna as client
Government Contracts
Federal awards to Moderna, Inc. · USAspending
No federal contract awards found for Moderna, Inc..
U.S. Patents
Recent USPTO applications naming Moderna, Inc.
No USPTO patent applications found for Moderna, Inc..
Annual Financials
From MRNA's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B |
| Operating income | -$3.07B | -$3.94B | -$4.24B | $9.42B | $13.30B |
| Net income | -$2.82B | -$3.56B | -$4.71B | $8.36B | $12.20B |
| Diluted EPS | -$7.26 | -$9.28 | -$12.33 | $20.12 | $28.29 |
| Operating cash flow | -$1.87B | -$3.00B | -$3.12B | $4.98B | $13.62B |
| Cash and equivalents | $2.60B | $1.93B | $2.91B | $3.21B | $6.85B |
| Total assets | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B |
| Total liabilities | $3.69B | $3.24B | $4.57B | $6.74B | $10.52B |
| Shareholders' equity | $8.65B | $10.90B | $13.85B | $19.12B | $14.14B |
As Moderna, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 20, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in MRNA's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationNov 16, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeNov 13, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 6, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureSep 30, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 3.02, 8.01, 9.01Material agreement · Direct financial obligation · Unregistered sale of equitySep 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 31, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureJul 8, 2026
EDGAR ↗ - 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteMay 11, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 1, 2026
EDGAR ↗
About Moderna, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE
SEC CIK0001682852 ↗
Former namesModerna Therapeutics, Inc.





